Feasibility of Web-based CBT-I Intervention in Individuals With Multiple Sclerosis
26. august 2019 oppdatert av: Catherine Siengsukon, PT, PhD, University of Kansas Medical Center
Assessment of the Feasibility of a Web-based CBT-I Intervention to Improve Sleep Quality and Fatigue in Individuals With Multiple Sclerosis
Forty individuals with multiple sclerosis (MS) will be randomly assigned to a 6-week web-based cognitive behavior therapy for insomnia intervention (wCBT-I) or to wCBT-I plus biweekly support meetings with research personnel via phone or video.
Questionnaires will be used to assess sleep quality, fatigue, and satisfaction.
Recruitment, retention, attrition, adherence, and safety information will also be collected.
This study is significant because addressing insomnia symptoms through CBT-I could be a low-cost, low-risk, non-pharmacological options for improving sleep quality and MS symptoms in individuals with MS.
This study is innovative because CBT-I has never been delivered via a web-based application to individuals with MS which may increase access to services.
Studieoversikt
Status
Fullført
Forhold
Studietype
Intervensjonell
Registrering (Faktiske)
44
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Catherine Siengsukon
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 80 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- 18-80 years old
- diagnosis of MS by physician
- report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 6 months
- ≥10 on Insomnia Severity Index (ISI)
- English speaking
- reports access to internet service and phone
- has a high school diploma to serve as a proxy measurement of reading ability to ensure adequate reading ability to participate in the study.
Exclusion Criteria:
- known untreated sleep disorder (such as sleep apnea or restless leg syndrome)
- >3 on STOP BANG indicating risk of sleep apnea
- increased risk of restless leg syndrome
- nervous system disorder other than MS
- relapse and/or corticosteroid use in past 8 weeks
- score of ≥15 on the Patient Health Questionnaire (PHQ-9) indicating severe depression or endorse any suicidal ideation (answer 1, 2 or 3 on #9 of the PHQ-9)
- performs shift-work.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: cognitive behavioral therapy for insomnia (CBT-I)
Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
|
|
Eksperimentell: CBT-I + biweekly support
Participants randomized to this arm will participate in a 6-week web-based CBT-I program.
In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
|
The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
change in Insomnia Severity Index (ISI)
Tidsramme: baseline and week 8
|
The ISI is a valid and reliable measure of sleep difficulties and consists of 7 questions each rated on a 0-4 scale.
The range of scores on the ISI is 0-28, with ≥10 suggesting clinical insomnia
|
baseline and week 8
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
change in Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: baseline and week 8
|
The PSQI is a well-validated and reliable measure of sleep quality and consists of 9 items within 7 sleep categories.
The 7 sleep category scores are summed to form a single global score ranging from 0-21.
A global score of >5 reflects poor sleep quality
|
baseline and week 8
|
|
change in Modified Fatigue Impact Scale (MFIS)
Tidsramme: baseline and week 8
|
The MFIS consists of 21 items with 3 subscales: physical, cognitive, and psychosocial.
The score on the 21 items are scored with a range of 0-84 with a higher score indicating a greater impact of fatigue.
|
baseline and week 8
|
|
change in Fatigue Severity Scale (FSS)
Tidsramme: baseline and week 8
|
Fatigue Severity Scale (FSS) assesses the impact of fatigue on activities for the week prior and consists of 9 questions.
The mean of the 9 scores is calculated with a range of 0-7.
|
baseline and week 8
|
|
change in Multiple Sclerosis Impact Scale (MSIS)
Tidsramme: baseline and week 8
|
MSIS-29 is total of 29 items scale, with subscales of physical (20 items) and psychological (9 items).
Responses computed in a range from 0-100, and higher scores indicating a worse quality of life due to physical and physiological impacts of MS.
|
baseline and week 8
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. oktober 2018
Primær fullføring (Faktiske)
20. august 2019
Studiet fullført (Faktiske)
20. august 2019
Datoer for studieregistrering
Først innsendt
1. oktober 2018
Først innsendt som oppfylte QC-kriteriene
18. desember 2018
Først lagt ut (Faktiske)
21. desember 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. august 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. august 2019
Sist bekreftet
1. januar 2019
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00142464
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .